このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Sanofi India バランスシートの健全性

財務の健全性基準チェック /66

Sanofi Indiaの総株主資本は₹6.8B 、総負債は₹0.0で、負債比率は0%となります。総資産と総負債はそれぞれ₹13.6Bと₹6.8Bです。 Sanofi Indiaの EBIT は₹7.5Bで、利息カバレッジ比率-16.2です。現金および短期投資は₹2.5Bです。

主要情報

負債資本比率

₹0

負債

インタレスト・カバレッジ・レシオ	-16.2x
現金	₹2.48b
エクイティ	₹6.85b
負債合計	₹6.76b
総資産	₹13.60b

財務の健全性に関する最新情報

Is Sanofi India (NSE:SANOFI) A Risky Investment?

May 26

Does Sanofi India (NSE:SANOFI) Have A Healthy Balance Sheet?

May 10

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Sanofi India Limited (NSE:SANOFI)

Dec 21

Is Sanofi India (NSE:SANOFI) A Risky Investment?

May 26

Does Sanofi India (NSE:SANOFI) Have A Healthy Balance Sheet?

May 10

Sanofi India (NSE:SANOFI) Is Increasing Its Dividend To ₹490

Apr 02

Sanofi India (NSE:SANOFI) Is Increasing Its Dividend To ₹490

Feb 25

Estimating The Fair Value Of Sanofi India Limited (NSE:SANOFI)

Dec 10

財務状況分析

短期負債: SANOFIの短期資産 ( ₹8.8B ) が短期負債 ( ₹6.4B ) を超えています。

長期負債: SANOFIの短期資産 ( ₹8.8B ) が長期負債 ( ₹361.0M ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: SANOFIは負債がありません。

負債の削減: SANOFI 5 年前には負債がありませんでした。

債務返済能力: SANOFIには負債がないため、営業キャッシュフローでカバーする必要はありません。

インタレストカバレッジ: SANOFIには負債がないため、利息支払いの負担は問題になりません。

Sanofi India バランスシートの健全性

財務の健全性 基準チェック /66

主要情報

財務の健全性に関する最新情報

Is Sanofi India (NSE:SANOFI) A Risky Investment?

Does Sanofi India (NSE:SANOFI) Have A Healthy Balance Sheet?

Recent updates

Sanofi India Limited Announces Resignation of Radhika Shah as Head of Legal and Company Secretary

Sanofi India Limited Announces Cessation of Cyrus Aibara as Senior Director Diabetes

Price target decreased by 9.1% to ₹8,501

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: EPS: ₹29.61 (vs ₹53.37 in 2Q 2023)

Sanofi India Limited Announces Resignation of Nitin Joshi, Head - Supply Chain, Effective 31 July 2024

Sanofi India Limited to Report Q2, 2024 Results on Jul 26, 2024

Sanofi India Limited Announces Resignation of Shalini Menon, General Medicines Medical Head and India Medical Lead, Effective July 5, 2024

Less than half of directors are independent

Sanofi India Limited Appoints N. Suresh Babu as Sales & Customer Engagement Head Diabetes, Effective July 1, 2024

New major risk - Share price stability

Investor sentiment improves as stock rises 17%

Sanofi India Limited's (NSE:SANOFI) 25% Share Price Surge Not Quite Adding Up

Sanofi India Limited Announces Resignation of Shalini Menon as General Medicines Medical Head and India Medical Lead

First quarter 2024 earnings released: EPS: ₹59.31 (vs ₹82.67 in 1Q 2023)

Upcoming dividend of ₹117 per share

Sanofi India (NSE:SANOFI) Will Pay A Dividend Of ₹117.00

Sanofi India Limited Announces Appointment of Flovie Martins as Head of Corporate Communications and Corporate Social Responsibility

Sanofi India (NSE:SANOFI) Will Pay A Dividend Of ₹117.00

Sanofi India Limited Announces Resignation of Marc-Antoine Lucchini as Non-Executive Director from the Board of Directors, Member of the Nomination and Remuneration Committee

Sanofi India (NSE:SANOFI) Is Due To Pay A Dividend Of ₹117.00

Sanofi India Limited Announces Resignation of Marc-Antoine Lucchini as Non-Executive Director, Member of the Nomination and Remuneration Committee

Sanofi India's (NSE:SANOFI) Dividend Will Be ₹117.00

Final dividend of ₹117 announced

Upcoming dividend of ₹50.00 per share

Price target increased by 8.8% to ₹9,371

Full year 2023 earnings released: EPS: ₹262 (vs ₹269 in FY 2022)

Sanofi India Limited, Annual General Meeting, May 14, 2024

Sanofi India Limited Recommends Final Dividend for the Financial Year Ended 31St December 2023, Payable on or After 24 May 2024

Sanofi India Limited to Report Q4, 2023 Results on Feb 23, 2024

Sanofi India Limited Appoints Radhika Shah as Head of Legal, Effective 15 January 2024

Risks To Shareholder Returns Are Elevated At These Prices For Sanofi India Limited (NSE:SANOFI)

Price target increased by 12% to ₹8,392

Third quarter 2023 earnings released: EPS: ₹65.95 (vs ₹56.84 in 3Q 2022)

Sanofi India Limited Announces the Resignation of Vaibhav Karandikar as Whole-Time Director

Sanofi India Limited to Report Q3, 2023 Results on Nov 08, 2023

Sanofi India Limited Appoints Surabhi Kaul as India People Director and Will Be Part of the Senior Management Personnel

Less than half of directors are independent

Sanofi India Limited Announces Executive Changes

Sanofi India Limited Announces Resignation of Vinita Korti Patil as Senior Legal Director - South Asia, Effective 7 December 2023

Second quarter 2023 earnings released: EPS: ₹53.37 (vs ₹52.28 in 2Q 2022)

Sanofi India Limited Announces Resignation of Gaurav Bahadur as People Director

Less than half of directors are independent

Sanofi India Limited to Report Q2, 2023 Results on Aug 10, 2023

Sanofi India Limited Announces Resignation of Annapurna Das as Non-Executive Director and Member of the Audit Committee, Effective 31 July 2023

Is Sanofi India (NSE:SANOFI) A Risky Investment?

Price target increased by 7.6% to ₹6,996

Full year 2022 earnings released: EPS: ₹269 (vs ₹410 in FY 2021)

Price target decreased by 7.9% to ₹6,604

Price target decreased by 8.5% to ₹6,986

Sanofi India Limited to Report Q4, 2022 Results on Feb 23, 2023

High number of new directors

Third quarter 2022 earnings released: EPS: ₹56.84 (vs ₹230 in 3Q 2021)

Sanofi India Limited Announces Change in Directorate

Sanofi India Limited to Report Q3, 2022 Results on Nov 03, 2022

Upcoming dividend of ₹193 per share

Price target decreased to ₹7,800

Second quarter 2022 earnings released: EPS: ₹52.28 (vs ₹77.42 in 2Q 2021)

Sanofi India Limited Approves One-Time Special Interim Dividend, Payable on August 22, 2022

Sanofi India Limited to Report Q2, 2022 Results on Jul 26, 2022

Does Sanofi India (NSE:SANOFI) Have A Healthy Balance Sheet?

First quarter 2022 earnings released: EPS: ₹104 (vs ₹63.35 in 1Q 2021)

Less than half of directors are independent

Sanofi India Appoints Rodolfo Hrosz as Managing Director

Sanofi India Limited to Report Q1, 2022 Results on Apr 26, 2022

Upcoming dividend of ₹490 per share

Full year 2021 earnings released: EPS: ₹410 (vs ₹207 in FY 2020)

Sanofi India (NSE:SANOFI) Is Increasing Its Dividend To ₹490

Sanofi India Limited Proposes Final Dividend for the Financial Year Ended December 31, 2021, Payable on or After May 4, 2022

Sanofi India (NSE:SANOFI) Is Increasing Its Dividend To ₹490

Sanofi India Limited, Annual General Meeting, Apr 26, 2022

Sanofi India Limited Approves Final Dividend for the Year Ended 31 December 2021

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

財務の健全性基準チェック /66